• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Friday 12/14/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

labs

  • 8:43 AM

    SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that ongoing research and development activities of the Company’s Co-Primer™ platform technology has yielded positive results in demonstrating the capabilities of Co-Primers in multiplex tests for SNP detection. The Company will utilize its proprietary design software and patent-pending Co-Primer technology to provide molecular testing solutions for use by customers. These include enterprise

    Read more
  • 2:54 PM

    SAN ANTONIO, TX–(Marketwired – Jul 6, 2015) – GenSpera, Inc. (OTCQB: GNSZ) announced today that it has entered into definitive agreements with institutional investors, led by a healthcare dedicated fund, for the private placement of shares of common stock and warrants to purchase shares of common stock for gross proceeds of $2.5 million. GenSpera will issue to the investors an aggregate of 3,571,430 shares of common stock at a purchase price of $0.70 per share. In addition, the Company will

    Read more
  • 7:10 PM

    SAN ANTONIO, July 30, 2014 /PRNewswire via COMTEX/ — GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the issuance of a United States patent entitled “Methods and compositions for the detection of cancer”. The patent US 8,772,226 B2 was issued July 8, 2014. The patent contains composition claims for thapsigargin-containing prodrugs that can be radiolabelled and then activated by the enzymes Prostate Specific Membrane Antigen (PSMA), Prostate Specific Antigen (PSA) or Human

    Read more
Public Wire Banner